| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma C Robert, L Thomas, I Bondarenko, S O'Day, J Weber, C Garbe, C Lebbe, ... New England Journal of Medicine 364 (26), 2517-2526, 2011 | 5256 | 2011 |
| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 2619 | 2019 |
| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 2612 | 2019 |
| Fluorouracil leucovorin and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer C Bokemeyer, I Bondarenko, A Makhson, JT Hartmann, J Aparicio, ... Journal of clinical oncology 27 (5), 663-671, 2009 | 2129 | 2009 |
| The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative … RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ... The lancet oncology 16 (1), 25-35, 2015 | 2018 | 2015 |
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 1905 | 2014 |
| Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous … M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ... The Lancet Oncology 17 (4), 425-439, 2016 | 1657 | 2016 |
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ... The Lancet 386 (9992), 444-451, 2015 | 1477 | 2015 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1379 | 2019 |
| Risk of natalizumab-associated progressive multifocal leukoencephalopathy G Bloomgren, S Richman, C Hotermans, M Subramanyam, S Goelz, ... New England Journal of Medicine 366 (20), 1870-1880, 2012 | 1374 | 2012 |
| RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor … NJ Robert, V Diéras, J Glaspy, AM Brufsky, I Bondarenko, ON Lipatov, ... Journal of clinical oncology 29 (10), 1252-1260, 2011 | 1192 | 2011 |
| Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind … TJ Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, ... Journal of clinical oncology 30 (17), 2046-2054, 2012 | 1173 | 2012 |
| Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma C Robert, JJ Grob, D Stroyakovskiy, B Karaszewska, A Hauschild, ... New England Journal of Medicine 381 (7), 626-636, 2019 | 1077 | 2019 |
| Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised … M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, ... The lancet oncology 15 (2), 143-155, 2014 | 1056 | 2014 |
| Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study C Bokemeyer, I Bondarenko, JT Hartmann, F De Braud, G Schuch, ... Annals of oncology 22 (7), 1535-1546, 2011 | 983 | 2011 |
| Overall survival with palbociclib and fulvestrant in advanced breast cancer NC Turner, DJ Slamon, J Ro, I Bondarenko, SA Im, N Masuda, M Colleoni, ... New England journal of medicine 379 (20), 1926-1936, 2018 | 967 | 2018 |
| Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non … MA Socinski, I Bondarenko, NA Karaseva, AM Makhson, I Vynnychenko, ... Journal of clinical oncology 30 (17), 2055-2062, 2012 | 840 | 2012 |
| Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ... J Clin Oncol 28 (30), 4594-4600, 2010 | 743 | 2010 |
| Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind … M Reck, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, ... Annals of Oncology 24 (1), 75-83, 2013 | 703 | 2013 |
| Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study GV Long, KT Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, ... Annals of Oncology 28 (7), 1631-1639, 2017 | 684 | 2017 |
